Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical proc…
Authors of this article are:
de Jong LAW Elekonawo FMK de Reuver PR Bremers AJA de Wilt JHW Jansman FGA Ter Heine R van Erp NP.
A summary of the article is shown below:
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become standard of care in the treatment of patients with peritoneal carcinomatosis of colorectal origin. The use of oxaliplatin for HIPEC has gained popularity. Although the HIPEC procedure is adopted throughout the world, major differences exist between treatment protocols regarding the carrier solution, perfusate volume, the use of an open or closed technique, duration of the perfusion and the application of additional flushing. These differences can influence pharmacokinetics and pharmacodynamics of oxaliplatin and may thereby impact efficacy and/or safety of the treatment. Clinicians should be aware of the clinical importance of pharmacology when performing HIPEC surgery. This review adds new insights into the complex field of pharmacology of HIPEC and highlights an important worldwide problem: the lack of standardisation of the HIPEC procedure.
Check out the article’s website on Pubmed for more information:
This article is a good source of information and a good way to become familiar with topics such as: HIPEC;hyperthermic intraperitoneal chemotherapy;oxaliplatin;peritoneal carcinomatosis;pharmacodynamics;pharmacokinetics;pharmacology;surgery.
Categories: Science News